CN1513458A - Compound silver zinc sulfapyrimidine ointment, and its prepn. method - Google Patents
Compound silver zinc sulfapyrimidine ointment, and its prepn. method Download PDFInfo
- Publication number
- CN1513458A CN1513458A CNA02160214XA CN02160214A CN1513458A CN 1513458 A CN1513458 A CN 1513458A CN A02160214X A CNA02160214X A CN A02160214XA CN 02160214 A CN02160214 A CN 02160214A CN 1513458 A CN1513458 A CN 1513458A
- Authority
- CN
- China
- Prior art keywords
- sulfadiazine
- grams
- zinc
- silver
- ointment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
A compound sulfapyrimidine silver zinc ointment for treating burn is prepared from sulfapyrimidine silver, sulfapyrimidine zinc, osmotic aid medical auxiliary, ethyl p-hydroxybenzoate, glycerine and distilled water through heating oil phase to 75 deg.C, heating water phase to 75 deg.C, slowly adding oil phase to water phase while stirring, cooling, adding sulfapyrimidine silver and sulfapyrimidine zinc, grinding, and examining. Its advantage is strong antibacterial function.
Description
Technical field
The present invention relates to a kind of medication preparation field, specifically is a kind of chemical medicine for external use-compound sulfadiazine silver zinc ointment and manufacture method for the treatment of burn.
Technical background
Burn is common a kind of wound of when peace in wartime, along with electric power produce and daily life in universal, and the use of chemicals in industry is even the burn number also is a lot of in peacetime.Burn is the infringement to the exocuticle skin, and burn wound causes the topmost approach of systemic infection.The treatment of doing a good job of it burn wound is the key of curing burn patient.Control infection promotes that healing is a target of implementing burn wound's treatment, also is the basic demand to external use burn treating medicine.
U.S. professor Fox invention silver sulfadiazin applied to clinical treatment in 1974, to control burn wound bacterial infection, especially bacillus pyocyaneus and colibacillary infection was played good control action.Thereafter Kai Fa sulfadiazine zinc salt except that having the prevention infection effect, also for wound surface provides zinc ion, helps tissue repair, promotes that wound surface heals faster.Up to today, silver sulfadiazine ointment and zinc sulfadiazine ointment are still the main medicine of present clinical treatment burn.Though silver sulfadiazine has stronger bacteriostasis, silver has astriction again, still can not satisfy the requirement of clinical promotion wound healing.Though and zinc salt can provide necessary zinc for wound healing, its antibacterial and bacteriostasis a little less than, can not satisfy clinical requirement.
Show that according to up-to-date experimentation the trace element the closest with the burn relation surely belongs to Zn.The Zn of about 60%-70% and albumin bound in human body, the Zn of small part combines with alpha2 Macroglobulin.The synthetic participation that needs Zn of nearly 60 plurality of enzymes all be unable to do without Zn at aspects such as synthetic, the epithelial repair of DNA, the metabolism of adjusting cellular immunization.There are some researches show that serum Zn lowers significantly in fire victim's the body, the degree of burn is heavy more, and losing of serum Zn is just many more.Rat blood serum Zn after scalding in the test reduces, and liver Zn increases, behind the additional zinc content, and the serum Zn rebound significantly of rat, the time of wound repair also obviously shortens.Test confirms that it is an important benefit Zn approach that percutaneous absorbs, and the mechanism of action of medicine for external use in burn wound's repair process that contains Zn becomes the hot subject of present burn treating research again.
The Chinese patent publication number is CN 1312078A, this disclosure of the Invention be a kind of manufacture method of compound sulfadiazine zinc spreader, prescription is: zinc sulfadiazine 0.5%-5%, silver sulfadiazine 0.2%-2.5%, medical accessory 1%-18%, glycerol 0-45%, medical calcium salt 0-5%, ethylparaben 0-0.08%, surplus is a distilled water; Technology is: add distilled water and make it swelling in medical accessory.Add all the other each components, stir evenly, boil, colloid mill breast mill evenly gets product.
Clinical practice shows that this liniment is not enough to the absorption of wound surface exudate, and a large amount of exudates are unfavorable for that medicine is in the wound surface film forming.And ooze out just burn just, mid-term wound surface characteristics, limited the use of liniment in the burn treating process.
Summary of the invention
The objective of the invention is to: overcome existing compound sulfadiazine zinc spreader shortcoming to the absorption difference of wound surface exudate in treatment burn process; Thereby provide a kind of the bacteriostasis antibiosis effect can be arranged, can have the compound sulfadiazine silver zinc ointment machin manufacture method of astringent effect to the wound surface exudate again.
The object of the present invention is achieved like this:
A kind of compound sulfadiazine silver zinc ointment provided by the invention comprises following composition:
Silver sulfadiazine 0.2-2.5wt%, zinc sulfadiazine 0.5-5wt%,
Permeation-promoter 1-10wt%, medical accessory 15-30wt%,
Ethylparaben 0-0.1wt%, glycerol 0-10wt%, surplus is a distilled water.
Described medical accessory comprises: glyceryl monostearate, stearic acid, white vaseline, lanoline, sodium lauryl sulphate.
Described permeation-promoter comprises: azone and/propylene glycol, when being azone and mixed with propylene glycol, its addition is 1-10wt%, but arbitrary proportion is arranged between them.
A kind of compound sulfadiazine silver zinc ointment method provided by the invention comprises:
1. by above-mentioned compositing formula, take by weighing oil each component: medical accessory 15-30wt% and permeation-promoter 1-10wt%; Put it into vessel in heating to fusing, and maintain the temperature between 60-80 ℃;
2. by above-mentioned compositing formula, take by weighing each component of water: the distilled water of ethylparaben 0-0.1%, sodium lauryl sulphate 15-30wt%, glycerol 0-10wt% and surplus; Extracting container puts it in addition, is heated to fusing equally, and maintains the temperature between 60-80 ℃;
3. then, the oil item is under agitation slowly joined in the water item, continue to stir, after the placement condensation silver sulfadiazine and zinc sulfadiazine are added, grind well, be sub-packed in sealing in the container, get product through check, packing, packing, chemical examination by same direction.
It mainly is to soak into corium by horny layer and active epidermis that local topical medicine percutaneous absorbs, and enters the body circulation through blood capillary.Skin is the barrier of percutaneous dosing to most drug, and after many drug transdermal administrations, infiltration rate does not reach the treatment requirement.So seeking the strong permeation-promoter that promotes drug transdermal to absorb is the key that strengthens the medicine for external use curative effect.Existing medical permeation-promoter is studied maximum azones and analog and polyalcohols.Mechanism of action is that azone infiltrates keratodermatitis, reduces the order that the iuntercellular lipid is arranged; Slough the duct that the iuntercellular lipid forms; Increase the horny layer water content; Reduce the phase transition temperature of horny layer lipid.Polyalcohols makes the keratin solvation, occupies proteinic hydrogen bonded position, reduces the combination between medicine-tissue; Other penetration enhancers of increase and usefulness are in cuticular distribution.The present invention selects for use azone and propylene glycol to share, and both synergism not only increase azone to cuticular action time and intensity, also can effectively shorten lag time, give full play to the effective efficiency of medicine.
The invention is characterized in it is with silver sulfadiazine, zinc sulfadiazine and medical permeation-promoter three share, and sulphonamides has stronger bacteriostasis antibiosis effect in this combination, and bacillus pyocyaneus and escherichia coli are all had stronger inhibitory action.Silver ion and DNA of bacteria effect suppress antibacterial, and silver salt has astriction, and minimizing is oozed out.Zinc salt provides zinc ion, helps tissue repair, promotes wound healing.Particularly add the permeation-promoter azone, it is a kind of high effect nontoxic, non-irritating dermal osmosis accelerator, with skin Permeability Measurer research, confirms that this composition can obviously reduce Skin Resistance, promotes the medicine percutaneous to absorb.
The present invention adds silver sulfadiazine and zinc sulfadiazine simultaneously in ointment, made up the treatment advantage of single sulfonamide, through splitting the checking of experiment and clinical efficacy, the present invention has given full play to two kinds of medicines therapeutic efficiency clinically, has synergistic function and good compatibility effect.The permeation-promoter that the present invention selects for use mainly is azone and propylene glycol, can better promote effective ingredient to go deep into wound tissue, has improved the degree of absorbing of externally-applied ointment.This preparation is applicable to the treatment burn, can reach antibiotic, anti-and infect, and promotes the dual function of wound healing.
Description of drawings
Fig. 1 quantification of subeschar bacteria dynamic observes
The specific embodiment
The present invention is described in detail below in conjunction with embodiment and preparation method:
Embodiment 1
The compound sulfadiazine silver zinc ointment prescription that present embodiment provides is: silver sulfadiazine 2 grams, zinc sulfadiazine 5 grams, azone 50 grams, ethylparaben 1.0 grams, glyceryl monostearate 85 grams, white vaseline 140 grams, sodium lauryl sulphate 8 grams, glycerol 110 grams, distilled water 600 grams.
Its preparation method: (1) gets the above-mentioned oil phase thing that weighs up: glyceryl monostearate 85 grams, white vaseline 140 grams, azone 50 grams; Put into beaker and be heated to fusing, keep about 75 ℃ of temperature;
(2) get the above-mentioned water-phase component thing that weighs up in addition: ethylparaben 1.0 grams, sodium lauryl sulphate 8 grams, glycerol 110 grams and distilled water 600 grams, put into beaker and be heated to fusing, keep about 75 ℃ of temperature;
(3) the oil-phase component thing after melting is slowly added aqueous phase, stir with same direction, after the placement condensation silver sulfadiazine and zinc sulfadiazine are added, grind well, the inspection of semifinished product, packing, packing, chemical examination get product.
Embodiment 2
Prescription 2 is: silver sulfadiazine 25 grams, zinc sulfadiazine 50 grams, azone 50 grams, ethylparaben 1.0 grams, glyceryl monostearate 50 grams, stearic acid 10 grams, lanoline 50 grams, white vaseline 100 grams, sodium lauryl sulphate 10 grams, glycerol 100 grams, distilled water 550 grams.
Its preparation method: (1) gets the above-mentioned oil phase thing that weighs up: glyceryl monostearate 50 grams, stearic acid 10 grams, lanoline 50 grams, white vaseline 100 grams and azone 50 grams; Put into beaker and be heated to fusing, keep about 75 ℃ of temperature;
(2) get the above-mentioned water-phase component thing that weighs up in addition: ethylparaben 1.0 gram,, sodium lauryl sulphate 10 grams, glycerol 100 grams and distilled water 550 restrain; Put into beaker and be heated to fusing, keep about 75 ℃ of temperature;
(3) oil-phase component after melting is slowly added aqueous phase, stir with same direction, silver sulfadiazine 25 grams and zinc sulfadiazine 50 grams are added after the placement condensation again, grind well, the inspection of semifinished product, packing, packing, chemical examination get product.
Embodiment 3
Prescription 3 is: silver sulfadiazine 10 grams, zinc sulfadiazine 10 grams, azone 20 grams, glycerol 100 grams, propylene glycol 30 grams, ethylparaben 1.0 grams, glyceryl monostearate 50 grams, stearic acid 10 grams, white vaseline 150 grams, sodium lauryl sulphate 10 grams, distilled water 609 grams.
Its preparation method: (1) gets the above-mentioned oil phase thing that weighs up: glyceryl monostearate 50 grams, stearic acid 10 grams, white vaseline 150 grams, azone 20 grams and propylene glycol 30 grams; Put into beaker and be heated to fusing, keep about 75 ℃ of temperature;
(2) get the above-mentioned water-phase component thing that weighs up in addition: ethylparaben 1.0 grams, glycerol 100 grams, sodium lauryl sulphate 10 grams and distilled water 609 grams; Put into beaker and be heated to fusing, keep about 75 ℃ of temperature;
(3) oil-phase component after melting is slowly added aqueous phase, stir with same direction, after the placement condensation silver sulfadiazine 10 grams and zinc sulfadiazine 50 grams are added, grind well, the inspection of semifinished product, packing, packing, chemical examination get product.
Embodiment 4
Prescription 4 is: silver sulfadiazine 15 grams, zinc sulfadiazine 30 grams, azone 50 grams, propylene glycol 50 grams, ethylparaben 0.2 gram, glyceryl monostearate 55 grams, stearic acid 15 grams, white vaseline 100 grams, sodium lauryl sulphate 10 grams, glycerol 100 grams, distilled water 580 grams.
Preparation method is with embodiment 1-3, get the oil phase heat fused, keep about 75 ℃ of temperature, other is heated to 75 ℃ at the phase constituent of fetching water, oil-phase component after the fusing is slowly added aqueous phase, stir, after the placement condensation silver sulfadiazine and zinc sulfadiazine are added with same direction, grind well, the inspection of semifinished product, packing, packing, chemical examination get product.
Embodiment 5
Prescription 5 is: silver sulfadiazine 15 grams, zinc sulfadiazine 40 grams, azone 100 grams, ethylparaben 1.0 grams, glycerol 50 grams, glyceryl monostearate 60 grams, stearic acid 10 grams, white vaseline 130 grams, sodium lauryl sulphate 10 grams, distilled water 590 grams.
Preparation method is with embodiment 1-3, get the oil phase heat fused, keep about 75 ℃ of temperature, other is heated to 75 ℃ at the phase constituent of fetching water, oil-phase component after the fusing is slowly added aqueous phase, stir, after the placement condensation silver sulfadiazine and zinc sulfadiazine are added with same direction, grind well, the inspection of semifinished product, packing, packing, chemical examination get product.
Embodiment 6
Prescription 6 is: silver sulfadiazine 10 grams, zinc sulfadiazine 10 grams, azone 30 grams, ethylparaben 1.0 grams, propylene glycol 30 grams, glycerol 50 grams, glyceryl monostearate 60 grams, stearic acid 10 grams, lanoline 100 grams, white vaseline 100 grams, sodium lauryl sulphate 10 grams, distilled water 590 grams.
Preparation method is with embodiment 1-3, get the oil phase heat fused, keep about 75 ℃ of temperature, other is heated to 75 ℃ at the phase constituent of fetching water, oil-phase component after the fusing is slowly added aqueous phase, stir, after the placement condensation silver sulfadiazine and zinc sulfadiazine are added with same direction, grind well, the inspection of semifinished product, packing, packing, chemical examination get product.
The experiment of embodiment 7 several anti Bacillus pyocyaneu Flugge curative effect of medication screenings
Adopt rat TBSA15% degree burn model, burn wound is coated with bacillus pyocyaneus (10
9/ be divided into 6 groups after ml), wherein 5 to form face and be coated with respectively with different pharmaceutical, matched group is coating not.By to respectively forming bacteria quantified and histopathology observation under face outward appearance, the crust, confirm that all compound sulfadiazine silver zinc ointment group anti-infective effect is best.
The animal grouping: rat is divided 6 groups, 10 every group.Four treatment groups are, 1-silver sulfadiazine ointment group, and 2-zinc sulfadiazine ointment group, 3-silver sulfadiazine+zinc sulfadiazine ointment group, 4-compound sulfadiazine silver zinc group, two matched groups are 5-ointment base+azone group, not treatment group of 6-.Tissue bacterial quantitative approach: after the aseptic method of crust undertissue is weighed, in the glass homogenizer of packing into, add diluent 2ml, carry out 10 times of gradient dilutions of series with diluent after the homogenate, liquid quantitative after every pipe dilution is splashed in the culture medium, and 37 were hatched 24 hours, chose the purpose bacterium and carried out colony counting.
Bacteria containing amount cfu/g=(specimen weight+2) * clump count * extension rate ÷ specimen weight
Table 1 crust undertissue bacillus pyocyaneus Quantitative Comparison (bacterium amount logarithm value ± standard deviation)
| Group sum 24h 48h 72h |
| ??1?????10?????4.09±0.81?????6.32±0.42?????6.64±0.55 ??2?????10?????4.66±0.52?????6.53±0.43?????6.75±0.33 ??3?????10?????4.41±0.59?????5.22±1.066????5.82±0.80 ??4?????10?????4.01±0.58?????5.00±0.69?????5.56±1.11 ??5?????10?????5.81±0.67?????7.18±0.67?????7.39±0.75 ??6?????10?????5.74±0.83?????6.69±0.45?????7.01±0.54 |
Treatment group and matched group compare: P＜0.05, compare with compound sulfadiazine silver zinc group: P＜0.01.In the treatment group, first group and other group comparison in the table: P＜0.05, P＜0.01.Second group of group and other group are relatively in the table: P＜0.05.
Claims (4)
1. compound sulfadiazine silver zinc ointment is characterized in that: comprise following composition:
Silver sulfadiazine 0.2-2.5wt%, zinc sulfadiazine 0.5-5wt%,
Permeation-promoter 1-10wt%, medical accessory 15-30wt%,
Ethylparaben 0-0.1wt%, glycerol 0-10wt%, surplus is a distilled water.
2. by the described compound sulfadiazine silver of claim 1 zinc ointment, it is characterized in that: described medical accessory comprises: glyceryl monostearate, stearic acid, white vaseline, lanoline or sodium lauryl sulphate.
3. by the described compound sulfadiazine of claim 1 silver zinc ointment, it is characterized in that: described permeation-promoter comprises: azone and/propylene glycol, when being azone and mixed with propylene glycol, its addition is 1-10wt%, but arbitrary proportion is arranged between them.
4. method for preparing compound sulfadiazine silver zinc ointment comprises:
(1), takes by weighing oil each component: medical accessory 15-30wt% and permeation-promoter 1-10wt% by above-mentioned compositing formula; Put it into vessel in heating to fusing, and maintain the temperature between 60-80 ℃;
(2) by above-mentioned compositing formula, take by weighing each component of water: the distilled water of ethylparaben 0-0.1wt%, sodium lauryl sulphate 15-30wt%, glycerol 0-10wt% and surplus; Extracting container puts it in addition, is heated to fusing equally, and maintains the temperature between 60-80 ℃;
(3) then, the oil item is under agitation slowly joined in the water item, continue to stir by same direction, after placing condensation silver sulfadiazine 0.2-2.5wt% and zinc sulfadiazine 0.5-5wt% are added, grind well, be sub-packed in sealing in the container, get product through check, packing, packing, chemical examination.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA02160214XA CN1513458A (en) | 2002-12-31 | 2002-12-31 | Compound silver zinc sulfapyrimidine ointment, and its prepn. method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA02160214XA CN1513458A (en) | 2002-12-31 | 2002-12-31 | Compound silver zinc sulfapyrimidine ointment, and its prepn. method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1513458A true CN1513458A (en) | 2004-07-21 |
Family
ID=34237818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA02160214XA Pending CN1513458A (en) | 2002-12-31 | 2002-12-31 | Compound silver zinc sulfapyrimidine ointment, and its prepn. method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1513458A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD4075C1 (en) * | 2009-12-31 | 2011-07-31 | Анатолий ЭФКАРПИДИС | Process for obtaining highly dispersed colloidal silver |
| CN102600363A (en) * | 2012-03-15 | 2012-07-25 | 沈慰平 | Traditional Chinese compound preparation for deep burnt wound restoration and tissue and skin regeneration promotion and preparation method of traditional Chinese compound preparation |
| CN106606510A (en) * | 2016-12-30 | 2017-05-03 | 常州市阳光药业有限公司 | Burn and scald ointment and preparation method thereof |
| CN113230200A (en) * | 2021-05-07 | 2021-08-10 | 浙江工业大学 | Ointment for treating bacterial skin diseases and preparation method thereof |
-
2002
- 2002-12-31 CN CNA02160214XA patent/CN1513458A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD4075C1 (en) * | 2009-12-31 | 2011-07-31 | Анатолий ЭФКАРПИДИС | Process for obtaining highly dispersed colloidal silver |
| CN102600363A (en) * | 2012-03-15 | 2012-07-25 | 沈慰平 | Traditional Chinese compound preparation for deep burnt wound restoration and tissue and skin regeneration promotion and preparation method of traditional Chinese compound preparation |
| CN102600363B (en) * | 2012-03-15 | 2014-03-19 | 沈慰平 | Traditional Chinese compound preparation for deep burnt wound restoration and tissue and skin regeneration promotion and preparation method of traditional Chinese compound preparation |
| CN106606510A (en) * | 2016-12-30 | 2017-05-03 | 常州市阳光药业有限公司 | Burn and scald ointment and preparation method thereof |
| CN113230200A (en) * | 2021-05-07 | 2021-08-10 | 浙江工业大学 | Ointment for treating bacterial skin diseases and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1032900C (en) | Metrohidazole formulations and therapeutical uses thereof | |
| CN107185031B (en) | A kind of biologically active medical dressing and preparation method thereof | |
| Adikwu et al. | Application of snail mucin dispersed in detarium gum gel in wound healing | |
| CN1302813C (en) | Transmission system for medicine containing trehalose and hyaluronic acid in use for curing burn and preparing method | |
| CN1513458A (en) | Compound silver zinc sulfapyrimidine ointment, and its prepn. method | |
| CN1843124A (en) | Nano silver coating agent for sterilization and its preparation method | |
| CN1251738C (en) | Chinese medicine for treating ashen nail and its preparation method | |
| CN116747152A (en) | Preparation method and application of recombinant III type humanized collagen liquid dressing | |
| CN113304325A (en) | Injectable and antibacterial dual-functional hydrogel and preparation method and application thereof | |
| CN102731630B (en) | Antioxidant oligopeptide with skin penetration capability | |
| CN1583165A (en) | Gel gent of Chiense forest frog bactericidal peptide | |
| CN101062054A (en) | Medicine for curing wound | |
| CN1201747C (en) | External applied medicine composition containing vitamin B | |
| CN102302442B (en) | Allicin vaginal suppository and preparation method thereof | |
| CN103251636A (en) | Medicament for treating Candida infections and diseases caused by Candida, and preparation method thereof | |
| CN1583166A (en) | Chinese forest frog bactericidal peptide spray agent and its preparation | |
| RU2460532C1 (en) | Preparation fastening wound healing | |
| RU2691144C1 (en) | Combined composition for treating infected wounds of various origins | |
| EP3524323A1 (en) | Wound healing agent having activity to promote antibacterial properties and wound healing properties | |
| CN1228986A (en) | Burn ointment | |
| KR20190099338A (en) | Preservative compositions and uses of compositions comprising polyvinylpyrrolidone and unityol | |
| CN1517125A (en) | Recombination human granul ocyte-macrophage colong stimulating factor ges and its preparation method | |
| RU2086233C1 (en) | Ointment for suppurative-inflammatory processes treatment | |
| CN108434437A (en) | A kind of compound ointment preparation and preparation method thereof | |
| de Sousa et al. | Toxicity study using rat (WISTAR) model of a hydrogel dressing with silver nanoparticles crosslinked and sterilized by gamma radiation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |